Pharmaceutical and biotech companies are using Contract Manufacturing Organizations (CMOs) more than ever for their drug development needs. The issue of how best to monitor these organizations, many of which are overseas and adhere to different regulatory standards, is a critical issue for the pharmaceutical and biotech industry. While costs are of key importance, there are other factors to consider in CMO selection.
Ajit Narang, Senior Research Investigator, Drug Product Science & Technology at Bristol Myers Squibb, noted in a recent interview with Pharma IQ: “Going with the lowest-cost CMO/CRO may not be desirable both in the short-term and the long-term for project success and building a strong relationship with an outsourcing partner.” Some key factors that should be considered when a company is looking to select a CMO/CRO for their specific needs are discussed in the interview, available in its entirety here:
The 13th Contract Manufacturing for Pharmaceuticals and Biotech Conference provides in-depth analysis to solve the top concerns in this sector, including reducing costs for drug development, ensuring compliance of CMOs, and keeping on the forefront of technology for developing successful partnerships between CMOs and the organization.
Key researchers and industry leaders from Sanofi-Aventis, Johnson & Johnson, Baxter Bioscience, Bristol Myers Squibb, Midas Pharmaceuticals and more will share case studies, best practices and hold interactive workshops to help companies benchmark against leading experts in the field.
For more information on the IQPC Contract Manufacturing for Pharmaceuticals and Biotech Conference, please visit http://www.pharmacontractmanufacturing.com or contact Program Director Emil Shteinberg at Emil.Shteinberg@
# # #